Longeveron (LGVN) Net Cash Flow Growth (1y) (2021 - 2026)
Longeveron (LGVN) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Longeveron | 14.87 Bn | 14.86 Bn | 264,000.00 | 326.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 326.24% |
| Dec 31, 2025 | -29.24% |
| Sep 30, 2025 | -110.48% |
| Jun 30, 2025 | -138.27% |
| Mar 31, 2025 | -63.01% |
| Dec 31, 2024 | -218.91% |
| Sep 30, 2024 | 1,433.72% |
| Jun 30, 2024 | 566.47% |
| Mar 31, 2024 | 45.48% |
| Dec 31, 2023 | 197.10% |
| Sep 30, 2023 | 88.27% |
| Jun 30, 2023 | -17.24% |
| Mar 31, 2023 | -56.52% |
| Dec 31, 2022 | -119.29% |
| Sep 30, 2022 | 6.27% |
| Jun 30, 2022 | 35.78% |
| Mar 31, 2022 | -114.91% |
| Dec 31, 2021 | 2,854.33% |
| Sep 30, 2021 | -2,577.36% |
| Jun 30, 2021 | -262.76% |